BOLT score test
Selected indexed studies
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. (BMJ, 2024) [PMID:38806195]
- Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. (Lancet, 2024) [PMID:38768626]
- Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. (Nat Med, 2024) [PMID:39277671]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Body Oxygen Level Test (BOLT) is not associated with exercise performance in highly-trained individuals. (2024) pubmed
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. (2024) pubmed
- Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. (2024) pubmed
- Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. (2024) pubmed
- Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. (2026) pubmed
- Contributions of Common, Rare, and Somatic Genetic Variants to Incidence of Atrial Fibrillation. (2025) pubmed
- Polygenic Prediction of Peripheral Artery Disease and Major Adverse Limb Events. (2025) pubmed
- Genetic Predisposition to Low-Density Lipoprotein Cholesterol and Incident Type 2 Diabetes. (2025) pubmed
- Transcatheter Aortic Valve Replacement With Intra-Annular Self-Expanding or Balloon-Expandable Valves: The Multicenter International NAVULTRA Registry. (2025) pubmed
- Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial. (2025) pubmed